Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Cash & Equivalents (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Cash & Equivalents data on record, last reported at $89.3 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 54.88% year-over-year to $89.3 million; the TTM value through Sep 2025 reached $89.3 million, up 54.88%, while the annual FY2024 figure was $55.5 million, 30.97% down from the prior year.
  • Cash & Equivalents reached $89.3 million in Q3 2025 per FHTX's latest filing, up from $72.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $213.6 million in Q1 2022 and bottomed at $50.6 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $83.1 million, with a median of $70.3 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: surged 1829.97% in 2021, then tumbled 76.3% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $101.1 million in 2021, then plummeted by 48.37% to $52.2 million in 2022, then surged by 53.86% to $80.3 million in 2023, then plummeted by 30.97% to $55.5 million in 2024, then skyrocketed by 61.1% to $89.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $89.3 million in Q3 2025, $72.6 million in Q2 2025, and $61.0 million in Q1 2025.